Population
Acanthamoeba myosin-II and cytoplasmic extracts
Comparison
Monoclonal and polyclonal antibodies that bind… vs Control antibodies that do not bind to myosin-II
Design
Preclinical
Authors
Loading...
No clinical implications for cardiovascular care; leaves open whether myosin-II tail domains regulate contractility in mammalian systems.
Specific monoclonal antibodies can inhibit Acanthamoeba actomyosin-II ATPase activity and gel contraction, revealing that structural domains in the myosin-II tail are involved in catalysis and energy transduction.
Kiehart et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: